New clinical trial data highlights the significant weight loss potential of survodutide in obesity management. The 68-week phase 3 SYNCHRONIZE-1 trial documented remarkable dose-dependent results: the highest dose of survodutide achieved a mean weight reduction of 17.5%, substantially outperforming the 1.2% reduction observed in the placebo group. Notably, over 60% of trial participants receiving the active medication reached the clinically meaningful threshold of 15% weight reduction. Intermediate doses also demonstrated efficacy, with 4.8 mg achieving 14.2% mean weight loss and 2.4 mg achieving 11.0%. The study enrolled 3,407 adults with obesity across diverse international sites, with participants maintaining a mean baseline BMI of 38.0 kg/m². These quantifiable results underscore survodutide’s potential as an effective pharmacological intervention for weight management when combined with lifestyle modifications.
Was this article helpful?
